For experts

2026. 05. 13

New C2H Report: Sacituzumab Govitecan (TRODELVY)

2026. 05. 13

New C2H Report: Teprotumumab (TEPEZZA)

2026. 04. 08

New C2H Report: Brivaracetam (Briviact)

2019. 03. 06

International symposium - Current status and future role of HTA in Japan and other countries